Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanaka Kazunari, Tsuji Kunihiko, Hiraoka Atsushi, Tada Toshifumi, Hirooka Masashi, Kariyama Kazuya, Tani Joji, Atsukawa Masanori, Takaguchi Koichi, Itobayashi Ei, Nishimura Takashi, Ishikawa Toru, Tajiri Kazuto, Tanaka Hironori, Toyoda Hidenori, Ogawa Chikara, Hatanaka Takeshi, Kakizaki Satoru, Kawata Kazuhito, Naganuma Atsushi, Kosaka Hisashi, Matono Tomomitsu, Ueda Yoshihide, Kuroda Hidekatsu, Yata Yutaka, Nishikawa Hiroki, Imai Michitaka, Aoki Tomoko, Ochi Hironori, Okamura Jumpei, Tamai Hideyuki, Nakamura Shinichiro, Nakamura Yoshiko, Yoshida Osamu, Nouso Kazuhiro, Morishita Asahiro, Itokawa Norio, Okubo Tomomi, Arai Taeang, Tsutsui Akemi, Nagano Takuya, Tada Fujimasa, Ohama Hideko, Koshiyama Yuichi, Kanayama Yuki, Noritake Hidenao, Komatsu Shohei, Fukumoto Takumi, Matsuura Takanori, Kim Soo Ki, Enomoto Hirayuki, Matsui Kosuke, Kaibori Masaki, Hiasa Yoichi, Kudo Masatoshi, Kumada Takashi, Real‐life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group
Аннотация
METHODS: We analysed 1464 patients with unresectable HCC treated with first-line systemic therapy between 2020 and 2025 across multiple centers. Patients were divided into training and validation cohorts. Restricted cubic spline-based interaction models were used to evaluate the association between baseline DCP and ORR according to treatment regimen. The predicted absolute difference in ORR (ΔORR) between regimens was examined across continuous DCP values, with a prespecified 10% threshold considered clinically meaningful. Robustness was assessed using leave-one-center-out and repeated random-split sensitivity analyses.
RESULTS: Overall ORR did not differ significantly between Atez/Bev and Dur/Tre. However, a significant interaction between baseline DCP and treatment regimen was observed in both cohorts. Atez/Bev showed a relatively stable ORR across DCP concentrations, whereas Dur/Tre showed a DCP-dependent increase in ORR. At low DCP levels, Atez/Bev was favoured; with increasing DCP levels, the relative benefit shifted toward Dur/Tre. Sensitivity analyses confirmed a consistent DCP-dependent transition pattern, although the DCP level at which ΔORR exceeded 10% varied across analyses, supporting a transition zone rather than a fixed cutoff.
CONCLUSIONS: Baseline DCP may modify the relative treatment benefit between Atez/Bev and Dur/Tre in unresectable HCC. Rather than defining a rigid cutoff, DCP appears to delineate a continuum in which higher levels increasingly favour Dur/Tre, providing a practical framework for individualized immunotherapy selection.